logo
Share SHARE
FONT-SIZE Plus   Neg

VIVUS Says FDA Extends Qnexa PDUFA Date

VIVUS Inc. (VVUS) said Monday that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the Qnexa New Drug Application by three months from April 17 to July 17, 2012.

On April 4, following the FDA's request, VIVUS submitted the Qnexa Risk Evaluation and Mitigation Strategy, which was considered a major amendment to the NDA. The submission consisted of proposed REMS materials.

Since the receipt date was within three months of the user fee goal date, the FDA is extending the Prescription Drug User Fee Act date by three months to provide time for a full review of the submission, the company noted.

The Qnexa NDA seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients with weight-related co-morbidities such as hypertension, type 2 diabetes or dyslipidemia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable company Altice USA Inc. increased Wednesday the number of shares it will sell in its initial public offering by 37%, raising around $1.9 billion. In the IPO, the company offered 63.94 million shares at a price of $30 per share, higher than the 46.6 million shares announced last month. Republican members of the Federal Communications Commission have taken steps toward repealing Obama-era net neutrality rules, but the results of a new Morning Consult/Politico poll found broad support for the regulations. Sixty-percent of respondents in the survey said they support the net neutrality rules. Music streaming service Spotify is testing a new ad unit called "Sponsored Songs" on its free service, enabling labels to promote songs on playlists for a fee, TechCrunch reported. Instead of appearing as ad banners like the platform's existing ads, labels can pay to have sponsored songs appear on playlists followed by a user, according to the report.
comments powered by Disqus
Follow RTT